Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes.

Cavazza A, Cocchiarella F, Bartholomae C, Schmidt M, Pincelli C, Larcher F, Mavilio F.

Gene Ther. 2013 Sep;20(9):949-57. doi: 10.1038/gt.2013.18. Epub 2013 Apr 25.

PMID:
23615186
2.

Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors.

Moiani A, Miccio A, Rizzi E, Severgnini M, Pellin D, Suerth JD, Baum C, De Bellis G, Mavilio F.

PLoS One. 2013;8(1):e55721. doi: 10.1371/journal.pone.0055721. Epub 2013 Jan 31.

3.

Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector.

Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A, Hoshino H, Miyoshi H, Asano S, Tani K.

Gene Ther. 2003 Aug;10(17):1446-57.

PMID:
12900759
4.

Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors.

Di Nunzio F, Maruggi G, Ferrari S, Di Iorio E, Poletti V, Garcia M, Del Rio M, De Luca M, Larcher F, Pellegrini G, Mavilio F.

Mol Ther. 2008 Dec;16(12):1977-85. doi: 10.1038/mt.2008.204. Epub 2008 Sep 23.

5.

Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors.

Almarza D, Bussadori G, Navarro M, Mavilio F, Larcher F, Murillas R.

Gene Ther. 2011 Jul;18(7):674-81. doi: 10.1038/gt.2011.12. Epub 2011 Mar 3.

PMID:
21368897
7.
8.

A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes.

Serrano F, Del Rio M, Larcher F, Garcia M, Muñoz E, Escamez MJ, Muñoz M, Meana A, Bernad A, Jorcano JL.

Hum Gene Ther. 2003 Nov 1;14(16):1579-85.

PMID:
14577919
9.

Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.

Bosticardo M, Ghosh A, Du Y, Jenkins NA, Copeland NG, Candotti F.

Mol Ther. 2009 Nov;17(11):1910-8. doi: 10.1038/mt.2009.172. Epub 2009 Jul 28.

10.
11.

The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.

Haas DL, Lutzko C, Logan AC, Cho GJ, Skelton D, Jin Yu X, Pepper KA, Kohn DB.

J Virol. 2003 Sep;77(17):9439-50.

12.

Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter.

Kamata M, Liu S, Liang M, Nagaoka Y, Chen IS.

Hum Gene Ther. 2010 Nov;21(11):1555-67. doi: 10.1089/hum.2010.050. Epub 2010 Oct 6.

13.

Retroviral vectors for high-level transgene expression in T lymphocytes.

Engels B, Cam H, Schüler T, Indraccolo S, Gladow M, Baum C, Blankenstein T, Uckert W.

Hum Gene Ther. 2003 Aug 10;14(12):1155-68.

PMID:
12908967
14.

T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.

Zhao-Emonet JC, Marodon G, Pioche-Durieu C, Cosset FL, Klatzmann D.

J Gene Med. 2000 Nov-Dec;2(6):416-25.

PMID:
11199262
15.

Feline leukemia virus integrase and capsid packaging functions do not change the insertion profile of standard Moloney retroviral vectors.

Métais JY, Topp S, Doty RT, Borate B, Nguyen AD, Wolfsberg TG, Abkowitz JL, Dunbar CE.

Gene Ther. 2010 Jun;17(6):799-804. doi: 10.1038/gt.2010.24. Epub 2010 Mar 18.

16.

Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.

Choi JK, Hoang N, Vilardi AM, Conrad P, Emerson SG, Gewirtz AM.

Stem Cells. 2001;19(3):236-46.

17.
18.

Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.

Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J.

Gene Ther. 1999 May;6(5):715-28.

19.
20.

Transcriptional Silencing of Moloney Murine Leukemia Virus in Human Embryonic Carcinoma Cells.

Wang GZ, Goff SP.

J Virol. 2016 Dec 16;91(1). pii: e02075-16. Print 2017 Jan 1.

Supplemental Content

Support Center